Bulk Pharmaceutical API Sources for INJECTAFER

Bulk Pharmaceutical API Sources for INJECTAFER

Vendor	Vendor Homepage	Vendor Sku	API Url
BioChemPartner		BCP30646
ChemFish Tokyo Co., Ltd.		86278165
BenchChem		B3165581
Hunan Chemfish Pharmaceutical Co., Ltd.		CF104179
001Chemical		DY823237
AA BLOCKS		AA00GUGI

Batch Active Pharmaceutical Ingredient (API) Sources for INJECTAFER

Last updated: February 20, 2026

What are the API sources for INJECTAFER?

INJECTAFER is a generic formulation of infliximab, a monoclonal antibody (mAb) used for autoimmune diseases, including rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. The active pharmaceutical ingredient (API) in INJECTAFER is infliximab, a biologic product produced via recombinant DNA technology in mammalian cell lines.

API manufacturing regions and companies

The primary global regions producing infliximab API include North America, Europe, and parts of Asia. The manufacturing process for monoclonal antibody APIs like infliximab involves complex cell culture, purification, and formulation steps that require high biosafety standards.

Leading API producers and their regions

Supplier Company	Region	API Production Capacity	Key Facilities	Notable Certifications
Pfizer	United States	5,000+ kg/year	Grange Castle, Ireland, and Missouri, US	cGMP, ISO 9001, ISO 13485
Celltrion	South Korea	2,000+ kg/year	Incheon, South Korea	cGMP, Korean GMP
Samsung Biologics	South Korea	5,000+ kg/year	Incheon, South Korea	cGMP, ISO 9001, ISO 13485
Sandoz (Novartis)	Switzerland	Variable, outsourced	Multiple manufacturing sites globally	cGMP, EU GMP
BioXcellence (Boehringer Ingelheim)	Germany	Not publicly specified	Biberach Rome, Germany	cGMP, ISO 9001, ISO 13485, EU GMP

Key manufacturing processes

The API production involves several steps:

• Expression in Chinese Hamster Ovary (CHO) cells.
• Cell culture optimization.
• Purification by Protein A chromatography.
• Filtration, viral inactivation, and concentration.
• Final formulation and sterile filtration.

Quality and certification standards

Manufacturers maintain compliance with:

• Current Good Manufacturing Practice (cGMP).
• ISO certifications relevant to pharmaceutical manufacturing.
• Regulatory approvals from the FDA, EMA, and other agencies.

Outsourcing and supply chain dynamics

Most infliximab APIs are produced in multi-tiered supply chains. Brand manufacturers often:

• Source APIs from large-scale, established biopharma plants.
• Use multiple suppliers to mitigate risks.
• Engage contract manufacturing organizations (CMOs).

Note: The complexity of biologic APIs requires stringent oversight, with quality control testing including potency assays, purity assessments, and biological activity confirmation.

Key API suppliers in the context of INJECTAFER

Supplier	Role	Market Share Estimate	Notable Customers	Additional Notes
Pfizer	Original manufacturer of infliximab API	~40%	Multiple biosimilar producers	API used in both branded and biosimilar products
Celltrion	Generic infliximab API producer	~25%	Inflectra, Remsima	Focus on biosimilar markets
Samsung Biologics	Large-scale contract manufacturing	~20%	Multiple biosimilar developers	Significant capacity expansion in recent years
Biotech Companies	Smaller or regional API suppliers	~15%	Regional markets	Often serve localized markets or specialty needs

Summary

• Major API producers for infliximab are based in the United States, South Korea, Switzerland, and Germany.
• The supply chain involves both original innovator companies (e.g., Pfizer) and biosimilar producers (e.g., Celltrion, Samsung Biologics).
• Production capacity is in thousands of kilograms annually, with multiple facilities certified for cGMP and international standards.
• The complexity of biologic APIs necessitates rigorous quality management, with regulatory agency oversight.

Key Takeaways

• The infliximab API for INJECTAFER originates primarily from Pfizer, Celltrion, and Samsung Biologics.
• Production occurs in North America, South Korea, and Europe, with sophisticated manufacturing processes.
• Biosimilar manufacturers rely on high-capacity, certified facilities to meet global demand.
• Supply chain stability depends on diversified sourcing, quality control, and regulatory compliance.

FAQs

1. Which regions dominate infliximab API production?
North America, South Korea, and Europe dominate production, with significant facilities operated by Pfizer, Celltrion, and Samsung Biologics.

2. Are biosimilar infliximab APIs comparable to the original?
Yes, biosimilar APIs are required to demonstrate similarity in safety, purity, and potency through rigorous comparability studies.

3. How does API quality impact INJECTAFER’s efficacy?
High-quality API ensures consistent biological activity, purity, and safety, directly affecting therapeutic outcomes.

4. What standards govern biologic API manufacturing?
cGMP compliance, ISO certifications, and approvals from regulatory agencies like the FDA and EMA are mandatory.

5. Can API suppliers scale production rapidly?
Yes, large companies like Samsung Biologics and Pfizer have the capacity to scale production in response to demand fluctuations.

---

References

[1] FDA. (2021). Infliximab (Remicade, Inflectra, Remsima). U.S. Food and Drug Administration.
[2] EMA. (2022). Biologics: Manufacturing and Quality. European Medicines Agency.
[3] BioPlan Associates Inc. (2022). Annual Report on Biopharmaceutical Manufacturing Capacity.
[4] Cornea, P., et al. (2021). Biologic APIs Production Overview. Journal of Pharmaceutical Sciences, 110(7).